Cargando…

Can physiologic colonic [(18)F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?

AIM: The development of biomarkers that can reliably and early predict response to immune checkpoint inhibitors (ICIs) is crucial in melanoma. In recent years, the gut microbiome has emerged as an important regulator of immunotherapy response, which may, moreover, serve as a surrogate marker and pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sachpekidis, Christos, Stein-Thoeringer, Christoph K., Kopp-Schneider, Annette, Weru, Vivienn, Dimitrakopoulou-Strauss, Antonia, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547632/ https://www.ncbi.nlm.nih.gov/pubmed/37452874 http://dx.doi.org/10.1007/s00259-023-06327-9

Ejemplares similares

The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Application of the long axial field-of-view PET/CT with low-dose [(18)F]FDG in melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2022)

Assessment of early metabolic progression in melanoma patients under immunotherapy: an (18)F-FDG PET/CT study
por: Sachpekidis, Christos, et al.
Publicado: (2021)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Interim [(18)F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Quantitative, Dynamic (18)F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined (18)F-FDG and (18)F-FLT PET/CT imaging
por: Sachpekidis, C., et al.
Publicado: (2018)

Functional Imaging with (18)F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient
por: Sachpekidis, Christos, et al.
Publicado: (2017)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Application of an artificial intelligence-based tool in [(18)F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2023)

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab
por: Breki, Christina-Marina, et al.
Publicado: (2016)

Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study
por: Kosmou, Anastasia, et al.
Publicado: (2021)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2017)

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival
por: Schank, Timo E., et al.
Publicado: (2021)

Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2023)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2020)

Positron Emission Tomography in Merkel Cell Carcinoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin α(v)β(3) Receptors
por: Liolios, Christos, et al.
Publicado: (2021)

Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients
por: Dimitrakopoulou-Strauss, Antonia, et al.
Publicado: (2012)

Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic (18)F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI
por: Papamichail, Dimitris, et al.
Publicado: (2019)

[(18)F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy
por: Mangas Losada, María, et al.
Publicado: (2023)

Characterization of multiple myeloma osseous lesions and diffuse infiltration pattern by 18F-FDG-PET/CT, static MRI and diffusion-weighted MR Imaging (DWI-MRI): a comparative multimodality imaging study
por: Mosebach, J, et al.
Publicado: (2014)

Basic and clinical immunology – 3032. 18FDG-PET/CT findings (SUV-MAX) are correlated with survival in stage-4 squamous cell carcinoma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [(18)F]-FDG PET/CT
por: Alberts, Ian, et al.
Publicado: (2021)

Brain Metastases Unresponsive to Immunotherapy Detected by 18F-FDG-PET/CT in a Patient with Melanoma
por: Fonti, Rosa, et al.
Publicado: (2020)

Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring
por: Beuthien-Baumann, Bettina, et al.
Publicado: (2021)

Benign Colonic (18)F-FDG Uptake on Whole-Body FDG-PET Scan
por: Jang, Byung Ik
Publicado: (2012)

Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET/CT analysis
por: de Heer, Ellen C., et al.
Publicado: (2018)

(18)F-FDG PET-CT for Staging of Conjunctival Melanoma
por: Damian, Andres, et al.
Publicado: (2013)

Incidental SARS-CoV-2-related findings in asymptomatic patients in [(18)F]-FDG-PET/CT—potential insights
por: Alberts, Ian, et al.
Publicado: (2020)

(18)F-FBPA PET in Sarcoidosis: Comparison to Inflammation-Related Uptake on FDG PET
por: Watabe, Tadashi, et al.
Publicado: (2020)

Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
por: Kasper, Bernd, et al.
Publicado: (2013)

Colonic Malignant Melanoma: (18)F-FDG PET/CT Findings
por: Kaya, Eser, et al.
Publicado: (2018)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

The Role and Potential of (18)F-FDG PET/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics
por: Filippi, Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tte49ahn72ro741g1opfl7823n